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Abstract: The underexploited potential of the national economy results in a low 
standard of living and a poor investment environment. Due to the current 
condition of economic processes, Bulgaria ranks at the bottom in terms of its 
GDP compared to other EU member-states and is one of the countries with the 
fastest declining population in the world. Low competitiveness and 
innovativeness of Bulgarian enterprises underlie the lack of any serious 
economic progress. This finding is true even for the economic spheres which 
contemporary biotechnological innovations are based on and in which our 
country has real advantages in terms of its natural resources and climate. The 
objective of this research paper is to analyse the main economic aspects of Life 
sciences and to present some major European accomplishments and 
partnerships in the pursuit of competitive advantages by enterprises operating in 
the sphere of biotechnologies.  
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Introduction 
 
ife sciences and the biotechnology industry are defined as ‘the application 
of science and technology to living organisms as well as parts, products 
and models thereof, to alter living or non-living materials for the production 
of knowledge, goods and services’ (OECD, 2018, Commission of the European 
Communities, 2007). Life sciences and biotechnologies develop in several 
different fields that are labelled with different colours, i.e. red, green and white 
biotechnologies, in order to distinguish between the areas they are applied to.  
The term ‘Red biotechnology’ refers to applying genetic engineering and 
other scientific achievements in the use of living organisms (micro-organisms) for 
L 
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the purpose of developing new medical products and healthcare methods to 
improve the quality of life (Markova, 2007, p. 59).  
Green biotechnology is a new expanding field of modern biotechnologies. 
It refers to applying biotechnologies to economically significant varieties of plants 
in order to produce new crop varieties or improve existing ones (Markova, 2007, 
p. 83). 
White biotechnology refers to applying biotechnology to industrial 
production. It is based on the use of molds, bacteria, micro-organisms and 
enzymes in the production of goods and services (Markova, 2007, p. 107). 
Life sciences are the basis for the development of industrial production in 
economic areas such as healthcare and pharmaceuticals; processing industry 
and agri-food industry. Production practices which are based on biotechnologies 
contribute to improved healthcare and better quality of life. Over the last years, 
the EU has actively been seeking to encourage the use of alternative energy 
resources in bio-economics.1  
Research work in the sphere of life sciences goes beyond the 
development of national economies. The significance of life sciences must be 
approached from a global perspective, that is, in terms of their contribution to the 
development of global economy, employment, incomes, and improving the 
quality of the living environment. 
The issues that are subject to analysis in this paper are rendered crucial 
by the economic significance of biotechnological innovations. On the one hand, 
they affect the development of Bulgarian companies whose production is based 
on biotechnologies. On the other hand, biotechnological innovations have an 
immediate impact on the overall economic development of the country in terms 
of the contemporary requirements for ensuring a sustainable high-quality living 
environment. 
The thesis we define for this research is that Bulgaria has an enormous 
variety of natural resources that are the primary raw materials which bio-industrial 
enterprises use in their production. At the same time, the development of bio-
based production, research and development, and the establishment of 
partnerships between the participants in the bio-technological eco system are 
significantly lagging behind. One of the major tasks of this research, therefore, is 
to review the major economic fields to which Life sciences are applied, since they 
underlie bio-industrial development, and successful practices on the Old 
Continent in terms of putting bio-technological innovations into practice. In our 
opinion, regardless of the specific features of different economic environments, 
the conditions for developing bio-industries are universal in nature and good 
awareness about them is essential for actively employing and developing such 
innovations in Bulgarian economic environment. 
 
                                                          
1 Biofuels have certain natural advantages – they are renewable, their use 
contributes to reducing the emissions of greenhouse gases and to increasing the EU’s 
energy security, my note. 
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1. Major Spheres of Developing Bio-technological 
Innovations 
        
A key aspect of biotechnological innovations is their application in the 
industrial production that is related to public healthcare. One of the major features 
of the activity of enterprises operating in the healthcare sector is their focus on 
pharmaceutics. A biotechnology may be defined as a processing technology 
whose end product is not biological, but a chemical one, and whose results are 
widely applied in the pharmaceutical sector (Commission of the European 
Communities, 2007). Hence, the essential role of Life sciences and bioindustry 
in dealing with challenges such as the ageing of the population or fighting 
potential pandemics. Other prospective applications of biotechnological 
industries and research are genomics and genetic research, including the so-
called ‘advanced therapies’ that refer to tissue engineering, gene and cell 
therapies, and nanomedicine. Industrial biotechnologies are another issue that 
has attracted a lot of attention. There has been an upward trend in their 
development since the beginning of the 21st century as they offer an alternative 
to chemical technological processes and fossil fuels and have enormous 
potential in terms of their long-term economic and environmental benefits. A case 
in point is the fact that switching from chemical to biotechnological methods in 
the production of a group of commonly used antibiotics resulted in reducing the 
consumption of electricity by 37%, of solvents – by nearly 100% and a 90% 
decline in the quantity of waste water (Commission of the European 
Communities, 2007). We should note, though, that the implementation of 
biotechnological practices in production is much below the capacity of European 
industry. In addition to insufficient funding which European enterprises regularly 
point out, another factor that hinders the more dynamic growth in the market 
application of biotechnologies is the slow transfer of technologies.2  Two other 
fields of application of biotechnological innovations are primary production and 
the agri-food industry. Biotechnologies have a number of modern applications in 
primary production and in the agri-food industry which, although less obvious, 
are essential to the economy, to the environment and to public health. 
Nowadays, biotechnological production is mainly used in the so-called 
‘input’ sectors of the economy that relate primarily to animal breeding, 
diagnostics, production of fine chemicals (animal food additives) and coenzymes 
(Commission of the European Communities, 2007). The results are different 
products for diagnostics, veterinary medicine and vaccines that are of key 
significance to the treatment, control and monitoring of some of the most serious 
diseases that afflict animals.  
                                                          
2 The technology transfer may be defined as the movement (diffusion) of 
information, ideas, knowledge and know-how from R&D centres to innovator enterprises 
and vice versa. Scientific achievements and inventions are put into practice through 
technology transfer, my note. 
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The economic benefits from using biotechnologies go beyond their 
economic application. Biotechnologies are also used to select or improve specific 
characteristics of species. Examples include modified plants that are highly 
resilient to sharp changes in weather and have high production yield. We should 
note, though, that it is necessary to make accurate assessments and apply strict 
legal regulations to reduce the risks of using genetically modified plants and 
animals (GMOs) and prevent any potential harm on human health as a result of 
using them.  
 
 
Figure 1. Economic application of Life sciences   
Source: Research conducted by the author  
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2. Life Sciences and the Biotechnology Industry in Europe 
 
Europe is the continent where biotechnological productions have a 
comparatively favourable environment for development. Although the global 
economic leader, the USA, are also leaders in biotechnological production, the 
Old Continent has well established traditions and years of successful experience 
in the implementation of innovation-related practices and centralized policies. 
Over the last years, there have been considerable accomplishments in a number 
of practical developments that are based on biotechnologies in different 
economic spheres, especially in healthcare, in the agrarian sector, and in the 
food industry. Those spheres develop rapidly and offer a huge potential for the 
further development of many European enterprises and their production 
competitiveness, which accounts for the intense interest in biotechnologies on 
the continent.  
Europe’s industrial image has been changing dynamically over the last 
three decades due to the increasing number of enterprises that have started to 
employ the achievements of Life sciences and biotechnological innovations. This 
has produced positive results in a wide range of bio-based products and raw 
materials that are successfully sold across the globe. Accumulated knowledge 
and expertise in the field contribute to exploiting more efficiently that potential on 
a European and a global scale, including in terms of raising the economic 
potential and improving the quality of the living environment in countries with less 
developed economies. Therefore, the European Council (EC) and the European 
Parliament (EP) assigned the European Commission to develop a draft strategy 
for counteracting potential challenges and risks and efficiently benefiting from 
newly arising opportunities for social and economic development. The strategy 
was designed on the basis of Life sciences and biotechnologies and was adopted 
by the Commission in 2002. It includes thirty specific actions that were to be 
implemented by 2010, with the provision that the timeframe for their 
implementation could be extended to 2020.  This was the first strategy adopted 
at an EU level. Initially, the strategy was designed to cover a wide range of 
opportunities and measures for promoting the adoption of biotechnologies by EU 
member states in different sectors of the economy. Planned measures referred 
to actions in four specific areas: (1) harnessing the existing research, financial, 
etc. potential; (2) promoting the better management of biotechnological projects 
(through social dialogue, ethical compliance); (3) meeting global challenges 
(promoting scientific collaboration with developing countries) and (4) ensuring a 
high level of coherence in the whole range of related policies (СOM (2002) 27, 
23.1.2002). 
Although central European institutions have been working seriously to 
accomplish these objectives, in our opinion, most of the results that have been 
achieved so far relate to the activity of research and development centres and 
project teams in innovator enterprises. One of the major issues for Bulgarian 
enterprises seeking innovative solutions in terms of the economic applications of 
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Life sciences is the access to successful practices of the leaders in the 
development of biotechnologies. The next part of the research paper will 
therefore review some of those practices, the objective of the review being to 
identify their contribution to the economic development of the continent and to 
analyse the overall implementation of those practices in a highly competitive 
environment.  
         
2.1. European Practices for Smart Growth in Biotechnologies 
 
There are two major reasons for life sciences and biotechnologies to be 
on the European agenda – they create prerequisites for long-term economic 
growth, stable employment and high incomes through the sustainable 
development of a number of economic sectors and subsectors and provide 
opportunities for improving the quality of the living environment. Despite the 
success achieved so far by using newly developed products of better quality, 
there have been a number of challenges to the development of the biotechnology 
industry in Europe. They relate to intense global competition; ongoing reforms in 
public healthcare to reduce public expenses and to improve the access to health 
services; rising research and development (R&D) costs; strict government 
regulations and higher investment risk which complicate access to project 
funding and weaken the motivation of individual and institutional investors. Hence 
the effort of businesses to seek various alternatives for optimizing their activity. 
One of the solutions is the establishment of partnerships between scientific 
centres and business organisations in a similar line of business, since such 
partnerships contribute to enhancing the transfer of knowledge, ideas and 
innovations, and substantially reducing the risk related to innovations in 
bioindustry by sharing it. 
European countries that are leaders in innovations have realized the 
mutual benefits from log-term collaboration between partners creating an 
investment environment that is based on biotechnologies. On the one hand, it is 
in the interest of business organisations and project investors to fund scientific 
research and development, since this creates favourable prospects for the long-
term development of research and development centres. Governments, on the 
other hand, also benefit from that partnership between businesses and science 
centers, since bio-industrial enterprises create jobs, generate incomes and 
revenue to the budget, and on a macro-economic level bio-industry is predicted 
to become increasingly important to global economic growth. 
In terms of industry, biotechnological and pharmaceutical companies and 
equity investors 3 are the major players in identifying new opportunities for 
                                                          
3 Risk equity investors are individual (wealthy persons – business angels; friends; 
family investors) and institutional investors (companies specializing in funding -  Venture 
capital funds; SWORD - Stock and Warrant Off-Balance Sheet R&D companies) that 
provide project funding and expert consulting at each stage of the innovation project 
implementation in exchange for gaining a share of the enterprise equity, my note. 
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establishing strategic alliances and relationships. Risk capital has a major role in 
acquiring shares of ownership in enterprises that operate in the biotechnology 
sector. Furthermore, the economic application of the achievements of Life 
sciences in leading European countries is promoted as a result of that 
partnership with risk equity capital.  
 
2.2. Development of Red Biotechnologies – the Healthcare Sector 
 
Red biotechnology, which is based on genetic engineering and scientific 
accomplishments in using microorganisms to develop new products and 
methods for improving human healthcare and the quality of living, is one of the 
major economic bio-industrial applications of Life sciences that have been 
developing extremely dynamically on a global scale for more than two decades. 
Enterprises that speciliase in healthcare are predominantly medium-sized and 
large companies. Hence, the establishment of long-term partnerships with 
universities, science centres and hospitals is essential to the development of the 
sector, since it is larger business entities that have the capacity to fund and 
implement scientific research projects as a result of which improved and newly 
developed health products are launched on the market.  
The European Innovative Medicines Initiative (IMI) is one of the sources 
for successfully implementing projects in the field of medicine. It is a plan for long-
term partnership between the EU and the pharmaceutical industry in Europe 
whose major objective is to promote open collaboration in scientific research in 
order to advance developments and improve patient access to personalized 
medicines.4 The aim of the Initiave is to improve human health by speeding up 
the development of, and patient access to, innovative medicines, particularly in 
areas where the quality of health service is unsatisfactory. The focus of the 
Initiative is on facilitating the collaboration between the key players in health 
research and healthcare practice, including universities, research centres, 
pharmaceutical and other related industries, small and medium-sized 
enterprises, patient organisations and medicine regulators. The IMI is the world’s 
biggest public-private partnership (PPP) in the sphere of healthcare. This fact is 
supported by the enormous budget that has been allocated for innovative health 
projects for the 2014-2020 period, the sum amounting to EUR 3.3 billion (IMI, 
2013).  
Figure 2 presents the parties in the partnerships established under the 
IMI. As the figure indicates, R&D centres and universities are a key player, since 
they are the driving force of innovations and projects in the sphere of 
biotechnologies.  
 
                                                          
4 Those are medical products developed for a particular client, by taking into 
account the specifics of their organism and disease, my note. 
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Figure 2. Economic application of Life sciences 
Source: Research conducted by the author  
  
The Innovative Medicine Initiative is expected to create new opportunities 
for developing biotechnologies in immunological, respiratory, neurological and 
neurodegenerative medicine. An example of some significant achievements that 
have already been made due to the implementation of the Initiative is the first 
genetically engineered human pancreatic β-cell line that can survive in vitro and 
is expected to play a key role in diabetes research in future. The innovation was 
made by the French biotechnology company ‘Endocells’ in collaboration with 
academic entities (IMI, 2013).  
Another notable example is the Collaboration on the Optimisation of 
Macromolecular Pharmaceutical to Cellular Targets, the COMPACT5 project, 
which inspires opening new prospects for the development of pharmaceutical 
companies in Europe. The objective of the project is to encourage research for 
developing innovative medicines based on biological macro-molecules, such as 
protein/peptide nucleic acids (ribonucleic acid) (COMPACT, January 2014).  
In addition to healthcare, red biotechnologies contribute to the prospects 
for European growth based on the economic applications of Life sciences, since 
they also relate to the development of white biotechnology and similar bio-based 
industries. More specifically, this applies to the sustainable transformation of 
renewable resources into bio-based products or biofuels to gradually replace 
non-renewable energy resources since their industrial and household 
consumption results in the emission of harmful substances in the air and their 
                                                          
5 Collaboration on the Optimization of Macromolecular Pharmaceutical Access 
to Cellular Targets, my note.  
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extraction leads to changes in the geographical relief, pollution of agricultural 
land, waste accumulation at quarries, soil degradation and erosion, etc.   
 
2.3. Joint Initiatives for Developing Biotechnologies through Public 
Private Partnerships  
 
An outstanding example of a public private partnership in bio-industry is 
British practice where a number of innovative biotechnology projects have been 
implemented successfully in various spheres of the economy through PPP 
funding. A good case in point is the activity of the ‘Welcome Trust’ research 
charity, which provided initial capital of GBP 200 million to ‘Syncona’6, thus 
enabling the  company to invest a substantial financial resource (including its own 
contribution) into healthcare business and innovative technologies (Wellcome 
Trust, media release, 3 January 2013). The portfolio of the company is made up 
of a small group of enterprises (mainly healthcare companies whose number is 
less than 20) which deliver a wide range of healthcare services to their 
customers. The company applies a highly selective approach to its beneficiaries. 
The major criteria in the process of selecting an alternative innovative project is 
the quality of the healthcare services provided by the healthcare establishments 
and innovative spheres of health science and practice which focus on applied 
medical science. As a result of that substantial funding, the company is able to 
acquire shares of other companies (as a rule, between 20 and 30% of their 
equity) which raises further managers’ commitment to directly contribute to 
research and development with ideas, contacts with other centres, etc. This 
renders invested capital more profitable and raises the worth of acquired shares. 
At the end of the investment period, the cost of the initial investment is covered 
by selling acquired shares to an outside investor or through redemption of its own 
shares. 
The Biomedical Catalyst (BMC) is another example of successful 
collaboration between the public and the private sector in the sphere of 
biotechnologies. As a result of implementing the funding programme of the 
Technology Strategy Board (TSB) and the Medical Research Council (MRC) in 
Great Britain, a financial resource of GBP 180 million has been ensured. The 
programme is unique since it is designed to attract private entities, individual 
investors, and thus provide funds in collaboration with the Government. The 
initiative is open to academic scientific circles and to businesses, and aims at 
supporting scientific and practical activity in pharmaceutics, diagnostics and 
mobile healthcare. To this end, the organisation provides various grants to bio-
industrial companies at different stages of project executions – from seed funding 
                                                          
6 The company specializes in the sector of healthcare services in close 
collaboration with universities and R&D centres in Great Britain, author’s note. 
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(at the early stages of project implementation) to bridge funding (at the later 
stages of project implementation).7 
 
2.4. Development of Biotechnology Innovations Based on Clusters 
         
Clusters represent a type of cooperation between potential partners from 
interrelated industries, their major objective being to improve the overall 
production and commercial performance of the enterprises from a particular 
economic sector. Clusters may also be defined as a self-organised production 
system in which participants cooperate along vertical and horizontal ‘chains’ to 
generate additional value added and to raise their competitiveness (Dan, 2012). 
They are groups of enterprises that have already established some partnership 
relations. What brings them together are similar innovations, design, quality, 
product development and marketing. A major factor to the establishment of 
clusters are the incentives for the development of assets, technologies, 
infrastructure or joint investment projects that are in most cases beyond the 
potential of a single enterprise, regardless of its capacity or scale of production.  
Biotechnology clusters play a crucial role in the development of business 
sectors that are based on Life sciences. They contribute to industry growth and 
development in Europe by providing platforms for academia, industry, policy 
makers and investors platforms to interact and collaborate through the exchange 
of knowledge and experience. Practical outcomes and benefits from the 
existence of biotechnology clusters are in five major aspects – improved potential 
for innovation, commercialization, creation of spin-offs and start-ups,8 funding 
and investment attraction, business development opportunities.  
Biotechnology clusters in Europe are typically concentrated in Central and 
North Eastern regions and countries (see Figure 3). Those are countries with 
established traditions in Life sciences and biotechnology research and industry 
activity such as pharmaceuticals, chemicals, agri-production, and medical 
technologies. At present, the leading biotechnology companies that operate in 
the Healthcare sector are located in Belgium, Denmark, France, Germany, 
Sweden, Switzerland, Great Britain, Italy, Spain and Austria (Mizuho Industry 
Focus, 2018).  
 
                                                          
7 See more on: https://mrc.ukri.org/funding/science-areas/translation/biomedical-
catalyst/ 
8 We should note the relationship which exists between the development of 
entrepreneurship in the sphere of biotechnologies and the geographical location of 
clusters in the branch illustrated in Figure 3. 
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Figure 3. Geographical distribution of biotechnology clusters in Europe 
in 2018 
Source: research conducted by the author. 
 
2.5. Partnerships Between Biotechnology Companies  
and the Pharmaceutical Industry  
 
Biotechnologies are essential to the development of new medicines and 
the improvement of already existing ones. This is confirmed by the fact that by 
the end of 2018, sales of biotechnology products in the healthcare sector 
accounted for 25% of the global pharmaceutical market (Evaluate Pharma, 
2018). It should be noted that the research and development which are the result 
of establishing and developing long-term partnerships between biotechnology 
companies and the pharmaceutical industry shifts the focus of attention to the 
pursuit of high economic performance through increasing and expanding 
contacts between R&D units and businesses and sharing the risks that are 
inherent to the activity. The process is of mutual benefit since biotechnology 
companies are largely dependent on public grants and private funding of 
innovations by private investors and pharmaceutical companies, while 
successful practices increase the worth of enterprises and their equity. Typical 
partnership models include intellectual property (IP) sharing, co-development, 
in/out-licensing, joint ventures, investment, mergers and acquisitions (M&As).  
A notable trend that has occurred as a result of long-term partnerships 
between biotechnology companies and pharmaceutical companies, is the 
growing number of investors in Life sciences and biotechnologies projects who 
shift their interests from earlier stage pipelines toward later stage companies (see 
Figure 4). This shift of focus can be accounted for by the lower risk and 
uncertainty that are inherent to such projects, as well as the consequences of the 
2007 financial and economic crisis that led to the failure of a number of individual 
and institutional investors. In our opinion, if the positive trend in the development 
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of the global economy is preserved in the medium term and there are no major 
risks of a long-term global recession, it would be realistic to predict that more 
substantial financial resources will be re-allocated to early-stage innovation 
projects and pharmaceutical companies with an insignificant market share. One 
example of an early-stage venture firm is the risk investment company ‘Merck 
Ventures’. The portfolio of the company consists mainly of small companies, 
including start-ups, that specialize in the production of medicines through 
biotechnologies. The company is a market leader and has contributed to the 
establishment of long-term collaboration between R&D and the pharmaceutical 
industry, thus providing the opportunity for the development of a number of highly 
successful medicinal products.9 
Figure 4 presents the findings of an analysis of equity investments in Life 
sciences and biotechnologies in Europe according to the stage of development 
of innovator enterprises. The conducted analysis refers to the period from 2008 
to 2010 and to the year 2018.   
        
 
Figure 4. Funding of biotechnology projects in Europe according to the 
stage of development of innovator enterprises 
Source: Mizuho Bank analysis on Ernst & Young (EY), 2014, Research 
conducted by the author.  
 
Data presented by the research of the Japanese Investment Bank are 
indicative of the correlation between the global economic environment and the 
trend in global economic development and the interest of equity investors in 
biotechnological projects of start-ups and companies with long traditions, history 
and successful production practices.  
 
 
                                                          
9 The risk investment company ‘Merck Ventures’ has a budget of EUR 300 million 
for projects in Healthcare and Life sciences. Specialised investment teams in the 
company work in areas that of strategic importance to Merck’s core business, including 
the production of a new generation of medicines in the sphere of oncology, immunology 
and immuno-oncology; equipment and services for biotechnological research; and new 
business areas, such as digital medicine, my note. 
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3. The Market of Biotechnologies in Bulgaria 
 
A major characteristic of Bulgarian economy is its low innovativeness 
when compared to the EU average. Despite the low percentage of total annual 
expenditure on R&D (0.78% of the GDP for the year 2017, in contrast to the set 
goal that government expenditure on innovation development should amount to 
2% of the GDP by the year 2020), there are certain grounds for optimism for the 
Healthcare sector which, alongside technical and natural sciences, accounts for 
the major share of R&D expenses in the country.  
A research we conducted established that by the end of 2018, the number 
of biotechnology companies in the country was 81, and the number of employees 
working in them – 581, i.e. the average number of employees in an enterprise 
was 7 people. The total turnover of enterprises amounted to EUR 3.4 million at 
the end of the third quarter (ME, 15 October 2018).  
 
Table 1       
Summarised data about the biotechnologies market in the country  
for the year 2018. 
 
R&D  
in 
biotechnologies   
Turnover 
(in mln. 
EUR) 
Enterprises 
(number) 
Employees 
(number) 
Average 
number of 
employees 
in a 
company 
(number) 
3.4 81 581 7 
Source: ME, 2018, Research conducted by the author. 
         
Despite its limited scope, biotechnological production in the country 
accounts for a relatively high share of production. Contemporary achievements 
in the development of biotechnologies, technologies and science contribute to 
the development of a number of economic sectors like the production of lactic 
acid products (where lactic acid bacteria and enzymes are used to produce 
yoghourt, sour cream butter and a variety of cheeses); brewing (the major 
substrate that is used are germinated barley grains (malted barley), and 
Saccharomyces yeast cultures are used to start the process of fermentation); 
wine and liquor production (where products rich in carbohydrates are used as a 
substrate and are transformed into alcohol by adding highly productive 
Saccharomyces genus); production of vinegar that is based on the use of 
substrates containing alcohol to which selected acetic acid bacteria are added; 
production and use of bread yeast (single celled fungi). In addition to bread yeast, 
hydrolytic enzymes like amylase, cellulase and lipase are also used in the 
production of some breads and bakery products; production of bio fertilizers and 
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bio insecticide products (Ministry of Economy, Innovation Strategy for Smart 
Specialisation of the Republic of Bulgaria 2014-2020). 
A more detailed analysis of the development of innovative biotechnology 
projects in our country is a serious challenge. One of the major reasons is that 
research and development in the sphere of Life sciences and biotechnologies in 
Bulgaria is extremely limited. According to the findings of this research, in 2018, 
most of the employees in the field (a total of 581 people) were working in 
enterprises whose staff did not exceed 7 people, i.e. in micro- and small 
enterprises. This indicates the limited staff capacity for developing innovative 
projects as well as the lack of significant potential to attract funds, including from 
local commercial banks which are the primary source of funds for project 
implementation in the country.  
At present, there are several sources that could provide funds for 
developing innovative biotechnology projects in Bulgaria. Those are the InnovFin 
financial tools; the EU Research and Innovation Programme ‘Horizon 2020’; the 
Fund Manager of Financial Instruments (the Fund of Funds) that was established 
to provide financial support to scientific research; the Jeremie instrument; 
specialised venture capital funds (VC funds). This exhausts the options of 
financial support for R&D not only in the sphere of biotechnologies, but also for 
any innovative projects at a national level. The lack of any major achievements 
in the development of innovative biotechnology projects is supported by the fact 
that the total turnover of innovator enterprises in the country in 2018 was as little 
as EUR 3.4 million. There were no foreign purchases of local enterprises assets, 
which implies that there were no innovative projects designed to improve existing 
products or to develop new ones based on the achievements of biotechnologies. 
Bulgaria, therefore, has a very weak presence in terms of innovations on the 
European map and qualifies in the group of ‘Modest Innovators’ (Eurostat, 
European Innovation Scoreboard Interactive Tool, 2019). There are still some 
positive indications, mainly in terms of creating legal opportunities for practical 
research in the sphere of innovations, including that of biotechnologies. 
University science centres can create intellectual products and then sell them. 
To this end, university units will be allowed to establish companies whose activity 
will put into practice the results of their research, thus stimulating the creativity of 
research teams involved in different projects. Higher schools will be allowed to 
invest in companies whose line of business is one of these aspects:   
 Research, development and implementation of scientific products, 
innovative ideas, industrial research and development of new 
products and technologies; 
 Adoption and sale of scientific research products, including the 
delivery or design of equipment for producing innovative products and 
intellectual property items, as well as national and international 
registration of patents and trademarks; 
 Innovative intermediation for knowledge and technology transfer 
between technological centres and technological parks. 
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The draft proposal of the Ministry of Education and Science also provides 
that higher schools shall be authorized to have ownership in the companies with 
a minimum equity share amounting of no less than BGN 5,000. This is a 
reasonable proposal, despite the fact that it puts university R&D centres in a 
dependent position, which might limit the scope of their activity and call into 
question the efficiency of their management and overall business activity.   
Special attention should be paid to Measure 16.1 that has been designed 
to promote innovations. The focus of the Measure is on the funding of projects in 
agriculture and the development of biotechnologies, in particular, to promote their 
contribution to raising the performance of enterprises in the sector. The financial 
resources provided by the Measure for the next three-year period amount to BGN 
39,116 million. Those shall be allocated to projects in five priority project areas 
(DFZ [in English: State Fund Agriculture], 2019): 
 Fostering knowledge transfer and innovation in agriculture, forestry, 
and rural areas;  
 Improving the viability of farms and the competitiveness of all types of 
agriculture on a regional scale; promoting innovative technologies in 
agriculture; sustainable management of forests; 
 Promoting food chain organisation, including processing and 
marketing of agricultural products, animal welfare and risk 
management in agriculture; 
 Restoring, preserving, and enhancing ecosystems related to 
agriculture and forestry; 
 Promoting resource efficiency and supporting the shift towards a low 
carbon and climate resilient economy in the agriculture and food 
sectors and the forestry sector. 
 
 
Conclusion 
 
Innovations in biotechnology projects have been developing rapidly due 
to increased awareness about the need to significantly improve the quality of life. 
Contemporary global business seems to have realized the correlation between 
employing scientific achievements and creating added value as a result of input 
effort, entrepreneurship, capital and risk in a number of economic spheres to 
develop products that contribute to making the living environment more 
attractive. Statistics indicates that there has been a sustainable upward trend in 
life expectancy in advanced economics, a fact which supports the importance of 
biotechnological innovations in pharmaceutics, healthcare, agriculture and the 
food industry. 
Conducting research and development of Life sciences and putting their 
accomplishments into practice requires a number of favourable conditions that 
are equally important to all investment projects in innovations. This refers to 
biotechnologies, too, since their further development implies sufficient resources, 
highly qualified specialists, modern equipment, capital and a favourable 
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investment environment. High quality and quantity requirements in terms of the 
conditions required for the development of biotechnologies are some of the major 
reasons why these technologies have been developing dynamically in certain 
regions, while other regions tend to consume, rather than develop products by 
adopting the achievements of biotechnologies, despite their numerous benefits.  
This research focused on reviewing the activity of leading European 
clusters whose scientific and practical accomplishments in the development of 
biotechnologies have a major impact at a regional and a global scale. The 
analysis revealed that those clusters are predominantly located in two 
geographic regions of the Old Continent, that is, Central and Northern Europe. 
On the one hand, this is due to the fact that the countries with the most developed 
economies are situated in those parts of the continent, and on the other hand, 
those are countries with long-standing traditions and successful practices in Life 
sciences and especially in the development of scientific research and industries 
like the production of pharmaceuticals, chemicals, agri-products, medical 
technologies, foods and agriculture products.  
As a result of our research we can conclude that European economy is 
dramatically lagging behind in innovations, especially those in biotechnologies. 
The United States, Japan, South Korea and China are the leaders in research 
and development in the sphere. What is more, while the financial and economic 
crisis that began in the 2007 weakened the interest of risk capital in investments 
in innovative biotechnological projects on a global scale, there seem to have 
been no major positive developments in Europe in that aspect in the post-crisis 
years, either. In our opinion, in order to raise the competitiveness of European 
biotechnology enterprises significantly, it would be necessary to allocate much 
more substantial public financial resources to the scientific centres that work in 
collaboration with businesses and have the capacity required for producing high 
quality intellectual products to meet the needs of the production sector.  
It would not be realistic to predict that the overall competitiveness of the 
pharmaceutical sector in Europe could significantly improve provided that 
enterprises with smaller production capacity were involved. Market specifics 
clearly put in a more advantageous position larger established producers that 
have alternative sources of funding, high caliber staff and better material security 
and are therefore able to make economies of scale. Those enterprises can thus 
focus their efforts on improving their production capacity in terms of quality, as 
well as quantity. Nevertheless, government policies, which give priority to science 
centres, should be designed so as to substantially encourage the development 
of project innovations, and hence, the more notable presence of European 
biotechnology companies on a global scale.  
The findings of this research about Europe lagging behind in terms of 
biotechnologies development when compared to market leaders are even more 
applicable to Bulgarian economy. There proved to be no overall government 
strategy to support research in Life sciences, despite the availability of extremely 
favourable environmental conditions (e.g. weather, soils) for developing different 
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lines of businesses based on biotechnologies.10 The insignificant share of bio-
industrial production in the total GDP of the country means that the industry has 
very little impact upon the overall socio-economic development of the country. 
On the other hand, this indicates that the potential of bio-industrial production in 
Bulgaria has largely been underestimated despite the prospects it offers. Two of 
the prerequisites for promoting their development are the consistent work of the 
government in that aspect and a high level of initiative and involvement on behalf 
of science centres and businesses whose collaboration would be of mutual 
economic benefit.  
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